Neoantigen × AI
Daily research signal
45Brief

Geneos and West China launch Phase I II Neoantigen

Geneos Therapeutics initiates a Phase II trial for its personalized DNA neoantigen vaccine in high-risk HCC, while West China Hospital launches a Phase I study of an mRNA-lipid nanoparticle vaccine in ovarian cancer.trialtrial

On the methodological front, researchers demonstrate quantum neural networks for improved neoantigen prediction and analyze clinical data to refine immunogenicity profiling.PubMedFrontiers

7new stories2 in context
AI / MethodsyesterdayNew

Quantum convolutional HLA immunogenic peptide prediction (Q-CHIPP): Next-generation neoantigen prediction with quantum neural network.

Researchers have applied Quantum Convolutional Neural Networks (QCNNs) to neoantigen prediction, addressing limitations of classical models in handling noisy, small datasets. Using a 46-qubit hardware experiment with noise mitigation techniques, the study achieved a 6% increase in classification accuracy for MHC binding and immunogenicity prediction compared to classical baselines. This work demonstrates the potential of quantum computing to enhance precision in neoantigen identification.

europepmc · yesterday · Peters R, Rhrissorrakrai K, Bangalore Parthasarathy P, Ratner V, Gujarati TP, Tolunay M, S

06

01
Clinical2 days agoNew

GNOS-PV02 Personalized Neoantigen Vaccine and Plasmid Encoded IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

Geneos Therapeutics has launched a randomized, open-label Phase II study (NCT07722741) for GNOS-PV02, a personalized neoantigen DNA vaccine combined with plasmid-encoded IL-12 (INO-9012). The trial targets patients with high-risk hepatocellular carcinoma (HCC) who are disease-free post-resection, aiming to prevent recurrence. This marks a significant clinical step for Geneos in validating its DNA-based platform in a adjuvant setting.

clinicaltrials · 2 days ago · Geneos Therapeutics
02
Clinical2 days agoNew

A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery

West China Hospital is conducting a Phase I, single-arm dose-escalation study (NCT07724106) for NeoOVSV, an mRNA-lipid nanoparticle vaccine in stage II/III ovarian cancer. The trial evaluates safety and immunogenicity when the vaccine is administered alongside standard adjuvant chemotherapy and a PD-1 antibody. This represents an early-stage clinical evaluation of an mRNA platform in combination with checkpoint inhibition.

clinicaltrials · 2 days ago · West China Hospital
03
Clinical2 days agoNew

Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS

Providence Health & Services is operating an expanded access program (NCT07614048) for T-cells engineered to express TCRs targeting mutant KRAS-G12D. The intermediate-size IND treats advanced pancreatic and colorectal cancers in patients with specific HLA types. This provides real-world data on the feasibility of manufacturing and administering KRAS-targeted adoptive cell therapy outside of traditional trial structures.

clinicaltrials · 2 days ago · Providence Health & Services
04
Clinical3 days agoNew

Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics - Nature

A recent review in Signal Transduction and Targeted Therapy highlights the clinical translation of personalized mRNA vaccines, citing Moderna’s mRNA-4157 and BioNTech’s autogene cevumeran for reducing recurrence risk. The article contrasts these advances with the historical limitations of therapeutic cancer vaccines, noting Sipuleucel-T as the sole FDA-approved example to date. It outlines various vaccine platforms and the immunological challenges remaining in the field.

news · 3 days ago · Nature
05
Commercial3 days agoNew

NYKD: Nykode Therapeutics Presents Comprehensive Preclinical Data, Optimized Manufacturing, and Durable Clinical Immunogenicity for their Individualized Neoantigen Therapy VB10.NEO - Finansavisen

Nykode Therapeutics presented preclinical data, manufacturing optimizations, and durable clinical immunogenicity for its individualized neoantigen therapy VB10.NEO. The presentation highlights the company's progress in scaling production and demonstrating sustained immune responses in clinical settings. This update signals continued development momentum for Nykode’s platform technology.

news · 3 days ago · Finansavisen
06
AI / Methods3 days agoNew

A spatial view of tumor neoantigen recognition - Nature

A new Nature publication offers a spatial perspective on tumor neoantigen recognition, examining how antigen location within the tumor microenvironment influences immune response. The article likely explores the interplay between neoantigen presentation and local immune cell infiltration. This spatial context is critical for understanding why some predicted neoantigens fail to elicit clinical responses.

news · 3 days ago · Nature

02

Relevant work from earlier we're still surfacing — not today's news.